Clinical Trials Browser

INDUSTRY × Pleural Effusion, Malignant × Thoracic × Clear all

NCT04914598 2026-01-02

A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions

Phase 3 Active not recruiting

290 enrolled

Thoracic

Pleural Effusion, Malignant

NCT02649894 2025-12-11

SWIFT

Phase NA Completed

119 enrolled 16 charts

Thoracic

Pleural Effusion, Malignant

NCT05461430 2025-09-15

TraveraRTGx

Recruiting

200 enrolled

BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Anus Neoplasms, Appendiceal Neoplasms, Ascites, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Laryngeal Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Stomach Neoplasms, Thymoma, Vulvar Neoplasms, Pleural Effusion, Malignant, Carcinoma, Neuroendocrine, Cholangiocarcinoma, Carcinoma, Small Cell, Carcinoma, Pancreatic Ductal, Gastrointestinal Stromal Tumors

NCT06210685 2025-08-11

The ACES Study for Aseptic Pleural Effusion

Phase NA Active not recruiting

25 enrolled

Thoracic

Pleural Effusion, Pleural Effusion, Malignant

NCT06740019 2025-04-04

A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

Phase 1 Recruiting

30 enrolled

MyeloidThoracic

Myeloproliferative Disorder, Chronic, with Eosinophilia, Pleural Effusion, Malignant

NCT06726564 2024-12-10

A Study of MT027 in Patients with Pleural Malignant Tumors

Phase 1 Recruiting

18 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Neoplasm Metastasis, Pleural Effusion, Malignant

NCT04985357 2024-11-25

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Withdrawn

BreastEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Anus Neoplasms, Appendiceal Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Laryngeal Neoplasms, Lip Neoplasms, Lung Neoplasms, Mesothelioma, Mouth Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Paranasal Sinus Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Thymoma, Vulvar Neoplasms, Pleural Effusion, Malignant, Carcinoma, Neuroendocrine, Cholangiocarcinoma, Carcinoma, Ductal, Small Cell Lung Carcinoma

NCT00791154 2024-08-23